Thursday, 21 Mar 2019

You are here

A New Era? JAK inhibitors in the Management of RA

ACR 2018 has come and gone. It was a conference filled with a number of highlights. One thing from this conference which really stood out was the continued plethora of data on JAK inhibitors. First in RA, and now in psoriatic arthritis and psoriasis.

There was a time when the gold standard of a new biologic in RA was hitting an ACR 20/50/70 of 60%, 40% and 20% respectively in a MTX IR population. In the new era of JAK inhibitors, the expectations are now higher, where we often see ACR scores of 70/50/30 in the for the ACR 20/50/70 scores respectively in the same population.

At this conference, the presentation of data for upadacitinib and filgotinib, both JAK-1 selective inhibitors, have continued push the case for the widespread use of these agents. For example, the SELECT COMPARE study, assessing the efficacy of upadacitinib 15mg OD versus Humira 40mg EOW or placebo showed that upadacitinib was similar to Humira in most efficacy domains, but in most cases were numerically superior, in addition to being statistically significant in achieving the all important ACR 50 response. This adds the the growing number of studies which show that JAKs are at least non-inferior to a TNF inhibitor, but may in fact be considered superior, depending on how much you scrutinize the methadological basis of such a claim.

Another thing that I find striking as I reviewed multiple posters about JAK inhibitors is how quickly they seem to work. In both the upacitinib and filgotinib phase 3 trials, most patients notice a significant improvement in pain, and quality of life by even 1 week. This is similar to previous data presented on tofacitinib and baricitinib. Therefore, I expect JAK inhibitors as a class in general to work very quickly.

Although we still define a primary failure to a biologic as a lack of optimal response by 6 months of initiating, I would argue that this rule does not apply to the JAK family. Those who will respond will likely respond early, and we are likely doing patients a disservice by waiting until the 6 months to switch inadequate responders. Perhaps for this class, even 3 months may be sufficient to be considered a primary failure to a JAK inhibitor? This is something that I will be incorporating into my own clinical practice and will try to assess my JAK patients sooner rather than later, after initiating treatment, and switching out earlier if needed.

I still remain part of the old guard, who still use a TNF inhibitor as first line after failing DMARDs. This stems more from old habits and greater comfort level from past experience that anything else. However, as an rheumatologist/epidemiologist who tries to incorporate best evidence into practice, it is becoming increasingly tough to justify these old habits. I still think the TNFs are a great class of molecules and don’t plan on abandoning them, but I think it may be time to share the spotlight here.

Add new comment

More Like This

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

Does Smoking Cessation Reduce RA Risk?

Individuals who quit smoking and maintained their nonsmoking status over a long duration of time had a decreased risk of developing seropositive rheumatoid arthritis (RA), an analysis of two large prospective cohorts found. 

Remission Unlikely in RA

Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.